Outlook Therapeutics Inc
F:41O
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Cutia Therapeutics
HKEX:2487
|
CN |
|
H
|
Hamborner REIT AG
LSE:0MCG
|
DE |
|
L
|
LSB Industries Inc
SWB:LS3
|
US |
We don't have any information about 41O's insider trading.
Outlook Therapeutics Inc
Glance View
Outlook Therapeutics is a biopharmaceutical company focused on eye diseases, especially retinal conditions that can threaten vision. Its main work is to develop and seek approval for an ophthalmic version of bevacizumab, a drug designed to be used in the eye rather than in its original cancer-treatment form. The company does not sell a broad range of medicines. Its business is centered on developing, testing, and commercializing one main product candidate for wet age-related macular degeneration and related retinal uses. If approved, it would sell the treatment to ophthalmologists, retina specialists, hospitals, and clinics that treat patients with these chronic eye conditions. Outlook Therapeutics makes money, when it has a product on the market, by selling prescription drug product and by working through the drug approval and launch process with regulators and healthcare providers. Its role in the industry is narrow but important: it is trying to turn an established active ingredient into a purpose-built eye treatment with a delivery format aimed at retinal care.
What is Insider Trading?
Insider trading refers to the buying or selling of a company's stock by individuals with access to non-public, material information about the company.
While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.
Why is Insider Trading Important?
It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.
However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.
Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
